MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
MGMT
diagnostic
glioma
methylation
molecular markers
prognostic
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
14 02 2019
14 02 2019
Historique:
received:
03
05
2018
revised:
11
07
2018
accepted:
29
08
2018
pubmed:
7
9
2018
medline:
23
4
2020
entrez:
7
9
2018
Statut:
ppublish
Résumé
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Despite the strong evidence supporting the role of MGMT methylation status in prognostication, its routine implementation in clinical practice has been challenging. The methods and optimal cutoff definitions for MGMT status determination remain controversial. Variation in detection methods between laboratories presents a major challenge for consensus. Moreover, consideration of other clinical and genetic/epigenetic factors must also be incorporated into treatment decision making. In this review, we distill the available evidence to summarize our position on the optimal use of available assays, and propose strategies for resolving cases with equivocal methylation status and a framework for incorporating this important assay into research and clinical practice.
Identifiants
pubmed: 30189035
pii: 5090948
doi: 10.1093/neuonc/noy132
pmc: PMC6374759
doi:
Substances chimiques
Tumor Suppressor Proteins
0
DNA Modification Methylases
EC 2.1.1.-
MGMT protein, human
EC 2.1.1.63
DNA Repair Enzymes
EC 6.5.1.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-178Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Nucleic Acids Res. 2007;35(6):e41
pubmed: 17289753
Nucleic Acids Res. 2005 Aug 16;33(14):e128
pubmed: 16106041
J Clin Oncol. 2009 Dec 10;27(35):5881-6
pubmed: 19901104
Neuro Oncol. 2017 Mar 1;19(3):336-344
pubmed: 27688263
J Clin Oncol. 2008 Sep 1;26(25):4189-99
pubmed: 18757334
Oncotarget. 2016 Sep 20;7(38):61916-61929
pubmed: 27542245
Cancer Res. 1999 Feb 15;59(4):793-7
pubmed: 10029064
Acta Neuropathol. 2012 Jun;123(6):841-52
pubmed: 22249618
Acta Neuropathol. 2012 Oct;124(4):547-60
pubmed: 22810491
Lab Invest. 2007 Oct;87(10):1055-65
pubmed: 17700563
J Neurooncol. 2010 May;97(3):311-22
pubmed: 19841865
Clin Cancer Res. 2016 Oct 1;22(19):4797-4806
pubmed: 27143690
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
Nat Rev Neurol. 2014 Jul;10(7):372-85
pubmed: 24912512
Neuro Oncol. 2009 Aug;11(4):348-56
pubmed: 19224763
J Mol Diagn. 2008 Jul;10(4):332-7
pubmed: 18556773
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6
pubmed: 8790415
Acta Neuropathol. 2018 Apr;135(4):601-615
pubmed: 29368212
Acta Neuropathol. 2013 Jun;125(6):913-6
pubmed: 23670100
Lancet Oncol. 2016 Nov;17(11):1521-1532
pubmed: 27686946
Acta Neuropathol. 2014 Oct;128(4):561-71
pubmed: 25008768
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Clin Neuropathol. 2015 Sep-Oct;34(5):250-7
pubmed: 26295302
J Clin Oncol. 2016 May 10;34(14):1611-9
pubmed: 26976423
J Clin Neurosci. 2018 May;51:85-90
pubmed: 29483008
J Clin Oncol. 2009 Dec 10;27(35):5874-80
pubmed: 19901110
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
Clin Cancer Res. 2011 Jan 15;17(2):255-66
pubmed: 21097691
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Lancet Oncol. 2012 Jul;13(7):707-15
pubmed: 22578793
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
J Natl Cancer Inst. 2015 Jun 24;107(8):
pubmed: 26109106
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
J Mol Diagn. 2016 May;18(3):350-361
pubmed: 26927331
Neuro Oncol. 2009 Jun;11(3):281-91
pubmed: 18952979
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
JAMA Oncol. 2017 Jun 1;3(6):784-792
pubmed: 28097324
DNA Repair (Amst). 2007 Aug 1;6(8):1079-99
pubmed: 17485253
J Neurooncol. 2016 Jun;128(2):333-9
pubmed: 27029617
Acta Neuropathol. 2011 May;121(5):651-61
pubmed: 21287394
J Neuropathol Exp Neurol. 2016 Mar;75(3):246-55
pubmed: 26883115
J Cancer Res Clin Oncol. 2012 Nov;138(11):1789-97
pubmed: 22986811
Neuro Oncol. 2015 Nov;17(11):1425-7
pubmed: 26374690
J Neurooncol. 2015 Mar;122(1):179-88
pubmed: 25575938
J Mol Diagn. 2013 Sep;15(5):539-55
pubmed: 23871769
PLoS One. 2012;7(3):e33449
pubmed: 22428052
J Clin Oncol. 2011 Aug 1;29(22):3050-5
pubmed: 21709196
Cancer Res. 1997 Sep 1;57(17):3672-7
pubmed: 9288770
Neuro Oncol. 2002 Oct;4(4):278-99
pubmed: 12356358
Neuro Oncol. 2013 Mar;15(3):370-81
pubmed: 23328811
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
J Mol Diagn. 2016 Nov;18(6):864-871
pubmed: 27639200
Clin Transl Oncol. 2016 Apr;18(4):391-7
pubmed: 26289551
Pharmacol Ther. 1997;74(3):285-97
pubmed: 9352585
Cancer. 2012 Sep 1;118(17):4201-11
pubmed: 22294349
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Lancet Oncol. 2014 Sep;15(10):1100-8
pubmed: 25163906
PLoS Med. 2012;9(5):e1001216
pubmed: 22675273
J Clin Oncol. 2013 Nov 10;31(32):4085-91
pubmed: 24101040
Int J Cancer. 2012 Sep 15;131(6):1342-50
pubmed: 22139906
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Clin Epigenetics. 2016 May 05;8:49
pubmed: 27158275
Clin Cancer Res. 2013 Oct 1;19(19):5513-22
pubmed: 23948976
PLoS One. 2011 Jan 07;6(1):e16146
pubmed: 21249131